PL3442547T3 - Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu - Google Patents
Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmuInfo
- Publication number
- PL3442547T3 PL3442547T3 PL17783343.1T PL17783343T PL3442547T3 PL 3442547 T3 PL3442547 T3 PL 3442547T3 PL 17783343 T PL17783343 T PL 17783343T PL 3442547 T3 PL3442547 T3 PL 3442547T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- lactobacillus reuteri
- autism spectrum
- spectrum disorders
- Prior art date
Links
- 241000174237 Lactobacillus reuteri MM4-1A Species 0.000 title 1
- 208000029560 autism spectrum disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322946P | 2016-04-15 | 2016-04-15 | |
| PCT/US2017/027827 WO2017181158A1 (en) | 2016-04-15 | 2017-04-15 | Probiotic therapies for developmental disorders and other neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3442547T3 true PL3442547T3 (pl) | 2023-10-23 |
Family
ID=60042831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17783343.1T PL3442547T3 (pl) | 2016-04-15 | 2017-04-15 | Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11135252B2 (pl) |
| EP (2) | EP3442547B1 (pl) |
| DK (1) | DK3442547T3 (pl) |
| ES (1) | ES2954147T3 (pl) |
| FI (1) | FI3442547T3 (pl) |
| HR (1) | HRP20231030T1 (pl) |
| HU (1) | HUE062788T2 (pl) |
| LT (1) | LT3442547T (pl) |
| PL (1) | PL3442547T3 (pl) |
| PT (1) | PT3442547T (pl) |
| RS (1) | RS64503B1 (pl) |
| SI (1) | SI3442547T1 (pl) |
| WO (1) | WO2017181158A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3442547T1 (sl) * | 2016-04-15 | 2023-11-30 | Baylor College Of Medicine | Lactobacillus reuteri MM4-1A za uporabo pri zdravljenju ali preprečevanju motenj avtističnega spektra |
| KR102463809B1 (ko) * | 2019-05-24 | 2022-11-04 | 한국식품연구원 | 클로스트리디오이데스 디피실레에 항균 활성을 갖는 락토바실러스 파라카세이 WiKim0110 균주 및 이를 포함하는 조성물 |
| WO2021146316A1 (en) * | 2020-01-13 | 2021-07-22 | Scioto Biosciences, Inc. | Methods for treating or ameliorating autism and related disorders |
| WO2022147251A1 (en) * | 2020-12-30 | 2022-07-07 | The General Hospital Corporation | Methods and composition for the treatment of autism spectrum disorder |
| CN113180109B (zh) * | 2021-04-16 | 2022-02-18 | 段云峰 | 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用 |
| US12005044B1 (en) | 2022-11-29 | 2024-06-11 | Autism Therapeutics Inc. | Treatment of autism spectrum disorders with ergothioneine, selenoneine, or combinations thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413960A (en) | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
| CN1711101A (zh) | 2002-10-03 | 2005-12-21 | Pr药品有限公司 | 孤独症及相似障碍的治疗 |
| US7344867B2 (en) * | 2005-04-15 | 2008-03-18 | Eamonn Connolly | Selection and use of lactic acid bacteria for reducing inflammation in mammals |
| US9084434B2 (en) | 2006-09-27 | 2015-07-21 | Little Calumet Holdings Llc | Probiotic oral dosage forms |
| US20100063002A1 (en) * | 2007-03-13 | 2010-03-11 | Bernd Stahl | Method of improving skills with a composition comprising non-digestible saccharide |
| AU2009319257B2 (en) | 2008-11-03 | 2014-10-09 | Société des Produits Nestlé S.A. | A nutritional composition comprising probiotics and improving sleep patterns |
| EP2485744A4 (en) | 2009-10-09 | 2014-01-22 | Prothera Inc | COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED |
| EP2658401A2 (en) | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
| EP2609814A1 (en) | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of cognitive function |
| EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| SI3442547T1 (sl) * | 2016-04-15 | 2023-11-30 | Baylor College Of Medicine | Lactobacillus reuteri MM4-1A za uporabo pri zdravljenju ali preprečevanju motenj avtističnega spektra |
-
2017
- 2017-04-15 SI SI201731398T patent/SI3442547T1/sl unknown
- 2017-04-15 LT LTEPPCT/US2017/027827T patent/LT3442547T/lt unknown
- 2017-04-15 DK DK17783343.1T patent/DK3442547T3/da active
- 2017-04-15 WO PCT/US2017/027827 patent/WO2017181158A1/en active Application Filing
- 2017-04-15 PL PL17783343.1T patent/PL3442547T3/pl unknown
- 2017-04-15 US US16/093,593 patent/US11135252B2/en active Active
- 2017-04-15 HR HRP20231030TT patent/HRP20231030T1/hr unknown
- 2017-04-15 RS RS20230719A patent/RS64503B1/sr unknown
- 2017-04-15 EP EP17783343.1A patent/EP3442547B1/en active Active
- 2017-04-15 HU HUE17783343A patent/HUE062788T2/hu unknown
- 2017-04-15 PT PT177833431T patent/PT3442547T/pt unknown
- 2017-04-15 FI FIEP17783343.1T patent/FI3442547T3/fi active
- 2017-04-15 EP EP23168971.2A patent/EP4238573A1/en not_active Withdrawn
- 2017-04-15 ES ES17783343T patent/ES2954147T3/es active Active
-
2021
- 2021-08-24 US US17/445,827 patent/US20210379123A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3442547A1 (en) | 2019-02-20 |
| EP3442547B1 (en) | 2023-06-07 |
| US20190070226A1 (en) | 2019-03-07 |
| ES2954147T3 (es) | 2023-11-20 |
| RS64503B1 (sr) | 2023-09-29 |
| HUE062788T2 (hu) | 2023-12-28 |
| EP3442547A4 (en) | 2019-11-27 |
| LT3442547T (lt) | 2023-09-25 |
| DK3442547T3 (da) | 2023-09-04 |
| WO2017181158A1 (en) | 2017-10-19 |
| FI3442547T3 (fi) | 2023-09-05 |
| US11135252B2 (en) | 2021-10-05 |
| SI3442547T1 (sl) | 2023-11-30 |
| HRP20231030T1 (hr) | 2023-12-22 |
| EP4238573A1 (en) | 2023-09-06 |
| US20210379123A1 (en) | 2021-12-09 |
| PT3442547T (pt) | 2023-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279752A (en) | Polycyclic compounds and their use in the treatment of immune disorders | |
| PL3212208T3 (pl) | Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia | |
| IL271117B (en) | Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders | |
| LT3442547T (lt) | Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai | |
| ZA201900869B (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| GB2549277B (en) | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder | |
| GB2549278B (en) | Use of cannabidivarin in the treatment of autism spectrum disorder | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| GB2548930B (en) | Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention of or treatment of ataxic disorder | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and their uses | |
| PT3197556T (pt) | Composição para a prevenção e/ou tratamento de sintomas de alergia | |
| HUE065202T2 (hu) | Készítmény bélelváltozások kezelésében való felhasználásra | |
| IL252493B (en) | Compounds for use in the prevention or treatment of cancer | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
| EP3720449C0 (en) | COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF SALMONELLOSIS |